NCT00479180 is a Phase 1/Phase 2 clinical trial of Vascugel in Hemodialysis Access, sponsored by Pervasis Therapeutics, Inc.

Who is sponsoring NCT00479180?

NCT00479180 is sponsored by Pervasis Therapeutics, Inc.

What drugs are being tested in NCT00479180?

Interventions in NCT00479180: Vascugel, Placebo Comparator.

What condition does NCT00479180 study?

NCT00479180 studies Hemodialysis Access.

Is NCT00479180 still recruiting?

NCT00479180 is currently completed. Last updated 25 October 2011.

Last reviewed 2011-10-25 · How we verify

NCT00479180

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use

Completed Phase 1/Phase 2 Last updated 25 October 2011

What this trial tests

Phase 1/Phase 2 trial testing Vascugel in Hemodialysis Access in 65 participants. Completed in 1 June 2010.

Timeline

1 July 2006

Primary endpoint
1 June 2010

1 June 2010

Quick facts

Lead sponsor	Pervasis Therapeutics, Inc
Phase	Phase 1/Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	65
Start date	1 July 2006
Primary completion	1 June 2010
Estimated completion	1 June 2010
Sites	1 location across United States

Drugs / interventions tested

Vascugel — full drug profile →
Placebo Comparator

Conditions studied

Hemodialysis Access — all drugs for Hemodialysis Access →

Sponsor

Pervasis Therapeutics, Inc — full company profile →

Who can join

Adults 18 to 89, any sex, with Hemodialysis Access. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety of vascugel
Time frame: 6 months followed by 2.5 year extension

Sponsor's own description

Vascugel™ is safe when placed at the anastomotic site at the time of surgery during creation of an AV graft or fistula for hemodialysis access.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell matrix contact modifies endothelial major histocompatibility complex class II expression in high-glucose environment.
Nickmann M, Saemisch M, Wilbert-Lampen U, Nickel T, et al · · 2013 · cited 2× · PMID 24043258 · DOI 10.1152/ajpheart.00018.2013

Verify or expand the search:

Other recruiting trials for Hemodialysis Access

Currently open trials in the same condition.

NCT07372027 — Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00479180 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pervasis Therapeutics, Inc
Last refreshed: 25 October 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00479180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing